Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi-GI3
2025-521587-35-00Phase 3Authorised
- Sponsor
- Summit Therapeutics
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of ivonescimab in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Summit Therapeutics. Primary endpoint: Progression-free survival. Planned start Jun 2026; status: authorised.
02
Drugs
ivonescimab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2025-521587-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521587-35-00.